AggregoTV - NSCLC

AggregoTV - NSCLC

Osimertinib + Ipilimumab in EGFR-Mutated NSCLC

Dr Sonam Puri discusses a trial which explores the combination of osimertinib, an EGFR TKI with ipilimumab, a monoclonal antibody drug in patients with EGFR mutant NSCLC as first line treatment.

Disease-Free Survival in IMpower010 Trial: Adjuvant Atezolizumab in NSCLC

Dr Sanjay Popat discusses results of the IMpower010 trial in patients with version 7 TNM, stage 1b resected non-small cell lung cancer.

Bispecific Antibodies in Lung Cancer

Dr Benjamin Besse outlines the role of bispecific antibodies in treating lung cancer.


IMpower010: Adjuvant Atezolizumab Improves DFS in Resected Stage II-IIIA NSCLC

Dr Heather Wakelee talks on the findings of IMpower010, a Phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA NSCLC.

Candid Conversations in Lung Cancer: Discussing Biomarker Testing and Targeted Therapies

PeerView has partnered with the LUNGevity foundation to bring the patient perspective into education directed to oncology and pathology professionals, and highlight the importance of having open conversations...

Checkpoint Inhibitors - Alone or With Chemotherapy in Lung Cancer?

Should patients with lung cancer with high PD-L1 expression be treated with checkpoint inhibitors alone or a combined checkpoint inhibitor and chemotherapy regimen? Dr Bruna Pellini highlights this as a major unanswered question in the field.

Evolving Applications of ctDNA in Lung Cancer: MRD, Early Detection, and Molecular Profiling

Dr Vamsidhar Velcheti outlines some of the evolving uses of ctDNA in lung cancer including molecular profiling, early disease detection, and relapse prediction.

Immunotherapy as a Game-Changer in Multimodal Management of Lung Cancer

Chair, Dr Brendon M. Stiles, Dr Boris Sepesi, and Dr Catherine Shu discuss immunotherapy advances in lung cancer in this presentation.

Lung Cancer Nursing UK Session at BTOG

Dr Catherine Henshall discusses the session on lung cancer nursing in the UK which took place at BTOG 2021.

No One Missed—NSCLC Biomarker Testing

Dr Jorge Gomez and Andrea Ferris discuss "No One Missed", a new campaign to raise awareness about comprehensive biomarker testing which can reveal vital information that can help identify the appropriate treatment...

Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

Dr Patrick Y. Wen discusses adjuvant osimertinib in resected EGFR-Mutated NSCLC.

Novel Therapies on the Horizon for Lung Cancer

Dr Samreen Ahmed discusses novel therapies for lung cancer such as those targeting KRAS mutations and antibody-drug conjugates for the treatment of HER2-driven non-small cell lung cancer.

Multisystem Immune-Related AEs With Immunotherapy in NSCLC

Jarushka Naidoo gives an overview of a study investigating immune-related adverse events associated with immune checkpoint inhibitor therapy for the treatment of NSCLC.

NERO Trial: PARP Inhibitors for Chemosensitive NSCLC

Dr Dean Fennell shares an update on the randomized Phase II/III NERO study investigating PARP inhibitors in patients with NSCLC who have previously responded to chemotherapy.

Antibiotics Impact Outcomes With Pembrolizumab in NSCLC Patients

Dr David Pinato outlines the impact of host determinants on response to immunotherapy in patients with NSCLC, highlighting PD-L1 expression as a biomarker for pembrolizumab response.

Guideline-Recommended Molecular Testing in Early-Stage NSCLC

This is a multidisciplinary look at molecular testing in early-stage non-small cell lung cancer.

Using Clinical Trials to Drive Treatment Approaches in Lung Cancer

Dr Andrew Robinson discusses the importance of using clinical trials to drive treatment approaches and summarizes the role of immunotherapies in the treatment of squamous NSCLC...

Systemic Treatment of Non-Oncogene Addicted NSCLC With Brain Metastases

Dr Lizza Hendriks discusses the systemic treatment of patients with non-small cell lung cancer and brain metastases who are non-oncogene addicted.

What Are The Symptoms of NSCLC?


The symptoms of non-small cell lung cancer are not specific. Learn more here about the possible symptoms. 

Radiosurgery Followed by Tumor-Treating Fields for NSCLC Brain Metastases

Dr Minesh P Mehta discusses radiosurgery followed by tumor-treating fields for NSCLC brain metastases.

Motivating Stage III NSCLC Patients to Stay on Treatment

Oncology specialists from a lung multidisciplinary team discuss best practices on motivating patients to stay on therapy.

Expert Video Report on Lung Cancer From ASCO 2020

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Egbert Smit comments on important and potentially practice changing study results in NSCLC.

Pembrolizumab for Non-Small Cell Lung Cancer Associated Brain Metastases

Dr Sarah B. Goldberg discusses the use of pembrolizumab for non-small cell lung cancer associated brain metastases.

Improving the Staging and Diagnosis of Patients With Stage III/IV Non-Small Cell Lung Cancer

Findings for Pathology and Pulmonary Medicine From a National Quality Survey, presented at the CAP 2020 Virtual Meeting.

Immunotherapy Trial Updates in NSCLC From ESMO 2020

Dr Roy Herbst discusses three abstracts presented at the ESMO 2020 virtual congress, including 5-year overall survival data from the KEYNOTE-024 study evaluating pembrolizumab versus CT in NSCLC...

CITYSCAPE: Tiragolumab Plus Atezolizumab for Non-Small-Cell Lung Cancer


The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab vs placebo + atezolizumab in patients with PD-L1-selected NSCLC.

ADAURA Results: Adjuvant Osimertinib for EGFRm Non-Small Cell Lung Cancer

Prof Roy Herbst speaks to ecancer about the abstract he presented at the 2020 ASCO Virtual Meeting on the results of the ADAURA trial.

BFAST: High Dose Alectinib for RET-Positive NSCLC

Dr. Nir Peled discusses the safety and efficacy results of high-dose alectinib treatment for patients with treatment naive RET-positive NSCLC in the Blood First Assay Screening Trial.

Phase II CodeBreak 100 trial of Sotorasib in Advanced NSCLC

Outcomes in patients with heavily pre-treated advanced NSCLC are very poor. To address this, the Phase II CodeBreak 100 trial investigated sotorasib, a first-in-class irreversible inhibitor...

NICE Approval: Brigatinib in ALK NSCLC

Dr. Raffaele Califano discusses the recent NICE approval of brigatinib for the treatment of patients with ALK-positive NSCLC who have not been previously treated with an ALK inhibitor.

Use of Liquid Biopsy in Stage IV Non-Small Cell Lung Cancer Patients

Considerations for use of liquid biopsy in Stage IV NSCLC are discussed by oncology specialists from a lung multidisciplinary team.

Key NSCLC Updates

Jarushka Naidoo outlines key NSCLC updates from the virtual Gathering Around Cancer 2020 Irish meeting, including novel targeted therapies designed for EGFR, ALK...

ESMO 2020 Highlights on Durability of Clinical Benefit and Biomarkers With AMG510 in NSCLC

David Hong reports on key results from ESMO Virtual Congress 2020 on 1257O: Durability of clinical benefit and biomarkers in patients with advanced NSCLC treated with AMG 510.

source list reference